力生制药(002393.SZ)：阿普米司特片通过上市许可申请

Core Viewpoint - The company, Lifesun Pharmaceutical (002393.SZ), announced that its subsidiary, Tianjin Central Pharmaceutical Co., Ltd., has received drug registration certificates from the National Medical Products Administration for Apremilast tablets in 10mg, 20mg, and 30mg specifications, indicating successful approval for market entry [1]. Group 1 - The drug Apremilast is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy [1].